Journal of Radiation Research
Online ISSN : 1349-9157
Print ISSN : 0449-3060
Regular Papers
Pretreatment with Rituximab Enhances Radiosensitivity of Non-Hodgkin's Lymphoma Cells
Ira SKVORTSOVABela-Andre POPPERSergej SKVORTSOVMaria SAURERThomas AUERRobert MOSERHans KAMLEITNERHeinz ZWIERZINAPeter LUKAS
著者情報
ジャーナル フリー

2005 年 46 巻 2 号 p. 241-248

詳細
抄録
The present study examines the effects of ionizing radiation in combination with rituximab (RTX), a chimeric human anti-CD20 monoclonal antibody, on proliferation, cell cycle distribution and apoptosis in B-lymphoma RL and Raji cells. Exposure to ionizing radiation (9 Gy) induced cell growth delay and apoptosis in RL cells, whereas Raji cells showed moderate radio-resistance. The simultaneous exposure of lymphoma cells to ionizing radiation and RTX (10 μg/mL) markedly enhanced apoptosis and cell growth delay in RL and Raji cells. Cooperative antiproliferative and apoptotic effects of RTX and radiation were achieved through the inhibition of c-myc and bcl-XL expression. Furthermore, RTX-modulated expression of cell cycle regulating proteins, such as p53, p21/WAF1, p27/KIP1, contributed to the development of radiation-induced cell killing and growth arrest. Each NHL cell line that underwent apoptosis induced by combination treatment revealed enhanced caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage as compared to only irradiated cells. These findings show that rituximab synergistically enhances radiation-induced apoptosis and cell growth delay through the expression of proteins involved in the programmed cell death and cell cycle regulation pathways.
著者関連情報

この記事は最新の被引用情報を取得できません。

© 2005 by Journal of Radiation Research Editorial Committee
前の記事 次の記事
feedback
Top